|Free Dividend Report|
|Stock Splits Calendar|
|LXRX Stock Split History|
|Preferred Stock Newsletter|
|LXRX Options Chain|
|Stock Message Boards|
Lexicon Pharmaceuticals (LXRX) has 1 split in our LXRX split history database. The split for LXRX took place on May 21, 2015. This was a 1 for 7 reverse split, meaning for each 7 shares of LXRX owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 142.857142857143 share position following the split.
When a company such as Lexicon Pharmaceuticals conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the LXRX split history from start to finish, an original position size of 1000 shares would have turned into 142.857142857143 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Lexicon Pharmaceuticals shares, starting with a $10,000 purchase of LXRX, presented on a split-history-adjusted basis factoring in the complete LXRX split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-1.84%|
|About Lexicon Pharmaceuticals|
|Lexicon Pharmaceuticals is a biopharmaceutical company. Co. discovers the functions and pharmaceutical utility of genes and uses those gene function discoveries in the discovery and development of pharmaceutical products for the treatment of human disease. Co. is developing LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain. Co. is also developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes. In addition, Co. is conducting preclinical research and development and preparing to conduct clinical development of compounds from a several additional drug programs. According to our LXRX split history records, Lexicon Pharmaceuticals has had 1 split.|
|LXRX Split History Table|
|05/21/2015||1 for 7|
|Healthcare Stock Splits|
|LXRX is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:
Also explore: LXRX shares outstanding history